

Supporting Information
for

Application of the Ugi reaction with multiple amino acids-derived components: synthesis and conformational evaluation of piperazine-based minimalist peptidomimetics


Mattia Stucchi,^a Silvia Cairati,^a Rengul Cetin-Atalay,^b Michael S. Christodoulou,^a Giovanni Grazioso,^c Gennaro Pescitelli,^d Alessandra Silvani,^{a,*} Deniz Cansen Yildirim^e and Giordano Lesma.^a

^aDipartimento di Chimica, Università degli Studi di Milano, via Golgi 19, 20133 Milano, Italy. ^bCancer Systems Biology Laboratory, Graduate School of Informatics, METU, 06800, Ankara, Turkey. ^cDipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, via L. Mangiagalli 25, 20133 Milano, Italy. ^dDipartimento di Chimica e Chimica Industriale, Università di Pisa, via Moruzzi 3, 56124 Pisa. ^eDepartment of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, Turkey.


Table of contents

¹ H and ¹³ C NMR spectra of compounds 5a and 5b	S2-S3
¹ H NMR spectra of intermediates 6-8	S4-S5
¹ H and ¹³ C NMR spectra of compounds 9a, 9b, 10, 11 and 12	S6-S10
¹ H and ¹³ C NMR spectra of compounds 13a and 13b	S11-S12
¹ H NMR spectra of intermediates 14-16	S13-S14
¹ H and ¹³ C NMR spectra of compounds 17a, 17b, 18, 19 and 20	S15-S19
¹ H and ¹³ C NMR spectra of compounds 23a, 23b, 24a, 24b, 25a, 25b, 26a and 26b	S20-S27
CD studies: Experimental UV and CD spectra of the major diastereoisomer 9b	S28
CD studies: calculated CD spectra for C-2(S) and C-2(R) isomers of 9	S28
Biological evaluation of compounds 9-12, 17-20 and 23-26	S29



Compound **5a**: ^1H NMR (300 MHz, CD_3CN)





Compound **5a**: ^{13}C NMR (75 MHz, CD_3CN)





Compound **5b**: ^1H NMR (300 MHz, CD_3CN)





Compound **5b**: ^{13}C NMR (100 MHz, CDCl_3)




Compound **6**: ^1H NMR (300 MHz, CD_3CN)





Compound **7**: ^1H NMR (300 MHz, CD_3CN)





Compound **8**: ^1H NMR (400 MHz, CDCl_3)



Compound **9a**: ^1H NMR (300 MHz, CD_3CN)




Compound **9a**: ^{13}C NMR (100 MHz, CD_3CN)




Compound **9b**: ^1H NMR (400 MHz, CD_3CN)




Compound **9b**: ^{13}C NMR (100 MHz, CD_3CN)





Compound **11**: ^1H NMR (400 MHz, CDCl_3)





Compound **11**: ^{13}C NMR (100 MHz, CDCl_3)





Compound **12**: ^1H NMR (400 MHz, CDCl_3)




Compound **12**: ^{13}C NMR (100 MHz, CDCl_3)





Compound **13a**: ^1H NMR (300 MHz, CDCl_3)





Compound **13a**: ^{13}C NMR (75 MHz, CDCl_3)





Compound **13b**: ^1H NMR (300 MHz, CDCl_3)





Compound **13b**: ^{13}C NMR (75 MHz, CDCl_3)





Compound **14**: ^1H NMR (300 MHz, CDCl_3)





Compound **15**: ^1H NMR (300 MHz, CDCl_3)





Compound **16**: ^1H NMR (300 MHz, CDCl_3)





Compound **17a**: ^1H NMR (300 MHz, CDCl_3)





Compound **17a**: ^{13}C NMR (100 MHz, CDCl_3)





Compound **17b**: ^1H NMR (400 MHz, CDCl_3)





Compound **17b**: ^{13}C NMR (100 MHz, CDCl_3)




Compound **18**: ^1H NMR (400 MHz, CD_3CN)




Compound **18**: ^{13}C NMR (100 MHz, CD_3CN)




Compound **19**: ^1H NMR (400 MHz, CD_3CN)




Compound **19**: ^{13}C NMR (100 MHz, CD_3CN)





Compound **20**: ^1H NMR (400 MHz, CD_3CN)





Compound **20**: ^{13}C NMR (100 MHz, CD_3CN)





Compound **23a**: ^1H NMR (300 MHz, CDCl_3)





Compound **23a**: ^{13}C NMR (75 MHz, CDCl_3)





Compound **23b**: ^1H NMR (400 MHz, CDCl_3)





Compound **23b**: ^{13}C NMR (100 MHz, CDCl_3)




Compound **24a**: ^1H NMR (300 MHz, CDCl_3)




Compound **24a**: ^{13}C NMR (75 MHz, CDCl_3)




Compound **24b**: ^1H NMR (400 MHz, CDCl_3)




Compound **24b**: ^{13}C NMR (100 MHz, CDCl_3)




Compound **25a**: ^1H NMR (300 MHz, CDCl_3)




Compound **25a**: ^{13}C NMR (75 MHz, CDCl_3)




Compound **25b**: ^1H NMR (400 MHz, CDCl_3)




Compound **25b**: ^{13}C NMR (100 MHz, CDCl_3)



Compound **26a**: ^1H NMR (300 MHz, CDCl_3)



Compound **26a**: ^{13}C NMR (75 MHz, CDCl_3)



CD studies:




Fig. 1 Experimental UV (top) and CD (bottom) spectra of the major diastereoisomer **9b**, measured in acetonitrile solution (2.0 mM). Cell length 0.01 cm and 0.05 cm (expansion).




Fig. 2 Calculated CD spectra for C-2(S) and C-2(R) isomers of **9** with CAM-B3LYP/SVP//B3LYP/6-31G(d) method. Boltzmann averages at 300K; Gaussian bandshape with 0.3 eV width; red-shift 30 nm.

Biological evaluation (cytotoxicities of compounds 9-12, 17-20 and 23-26).

IC₅₀ values in Huh7 and Mahlavu cell lines.

Compound	Huh7			MV		
	IC50(μM)	R2	s.d	IC50(μM)	R2	s.d
12	15,2	1,0	1,8	11,3	0,9	0,4
25b	16,2	0,9	1,1	30,5	0,8	3,7

Non growth inhibition for compounds **9-11, 17-20, 23, 24, 25a** and **26**.